Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.

Name: Kaimen Rigor review — Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.
Item: Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.
Rating: 59
Author: Alpha1

Cooke GS, Hung LM, Flower B, McCabe L, Hang VTK, Thu VT, Thuan DT, Dung NT, Phuong LT, Khoa DB, An NTC, Thach PN, Huong VTT, Bich DT, Tuyen NK, Ansari MA, Le Ngoc C, Quang VM, Phuong NTN, Thao LT, Tran NB, Kestelyn E, Kingsley C, Van Doorn R, Rahman M, Pett SL, Thwaites GE, Barnes E, Day JN, Chau NVV, Walker AS

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3★ (Adequate), 0 critical, 2 high issues for “Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.

Read full text (PMC)

DOI

10.1016/S0140-6736(25)00097-2

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/aa776395-f75d-4f00-842e-34120838daef" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/aa776395-f75d-4f00-842e-34120838daef/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 2 high issues for “Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

7ebaf3f28c067dbfa2c675713b080ec60cc62463b8d04c7bb94489f0ec2f8658

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.

Paper source

Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsStatistic did not reproduce−0.5★
IntegrityIntegrity concern−0.5★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 4 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Printed percentage does not match its own count
highArithmeticrecomputedFull detail
98.7% does not match the reported count 151/152
“151/152 (98.7%)”
Find in source
02Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is sustained virological response (SVR), defined as undetectable HCV RNA 12 weeks after treatment completion. SVR is a surrogate marker for clinical outcomes such as prevention of cirrhosis, hepatocellular carcinoma, and mortality. The manuscript does not provide evidence linking SVR to these hard clinical outcomes, nor does it demonstrate target engagement at the tested dose beyond the surrogate itself. Therefore, the efficacy claim rests on a surrogate without a validated link to clinical benefit.
“The primary endpoint was SVR, defined as plasma HCV RNA less than the lower level of quantification 12 weeks after the end of treatment without previous treatment failure.”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The induction–maintenance strategy is cost-saving.
“When treatment costs are proportional to the number of tablets used, the induction and maintenance strategy would be cost saving, although this is not the primary intent of the strategy.”
Discussion ¶8Find in source

Findings by category

201ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and thoroughly reported randomised controlled non-inferiority trial. The design is rigorous, ethical approvals are documented, and statistical methods are appropriate. Minor reporting gaps include threshold p-values, lack of explicit CONSORT statement, and absence of code sharing, but these do not undermine the overall integrity.

Both reviewers agreed on study type and all dimension statuses. The statistics verification component checked only 2 tests (1 consistent, 1 not flagged as error), so the statistical analysis is not fully verified. The citation check found no retracted or missing references. The claim audit flagged one overstated claim about cost-saving, which is addressed in the action items.

Numerical inconsistencies

2 findings · worst high

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks. 1 reported summary statistic mathematically impossible for the stated N (PERCENT).

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions overstated beyond the evidenceAssessed

7 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites WHO guidelines and notes the lack of randomised trials comparing the two regimens, establishing the need for the study. The rationale for testing novel strategies is supported by the need to expand access to treatment. Limitations of prior research are implicitly addressed by the trial design, though not explicitly detailed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work, identifying a gap in head-to-head comparisons, and providing a logical rationale for the study objectives.

Evidence

“No randomised trials have compared these treatment combinations and, in the absence of head-to-head comparisons and with high variability in generic pricing, countries differ in their choice of first-line treatment.”

Introduction ¶1Find in source

“In this Article, we describe the first randomised controlled trial of WHO-approved first-line treatments for HCV, designed to assess non-inferiority of sofosbuvir–daclatasvir versus sofosbuvir–velpatasvir, and to evaluate potential novel treatment strategies that could expand access to treatment using an efficient platform factorial design.”

Introduction ¶3Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research and identifying a gap in head-to-head comparisons of HCV treatments.

Evidence

Introduction ¶1Find in source

Introduction ¶2Find in source

Randomization used a computer-generated sequential list with permuted blocks, stratified by centre and genotype. The trial was open-label with a clear rationale, and efficacy endpoints were assessed by masked laboratory staff. Sample size calculations were provided for both the drug and strategy comparisons. Inclusion/exclusion criteria were specified, and the analysis populations (mITT, safety, per-protocol) were defined. Outlier handling is addressed through the definition of treatment failure and the per-protocol population.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, stratification, and pre-specified analyses, though blinding was not possible and was appropriately justified.

Evidence

“Randomisation used a computer-generated sequential list with variably sized permuted blocks prepared by the trial statistician (LM) and incorporated securely into the online trial database.”

MethodsFind in source

“The trial was open-label: no placebo was provided due to the complexity of ensuring that participants took the right pills on the right days. Masking of trial staff from randomised assignment was not possible, but efficacy endpoints were based on HCV viral loads assessed in the laboratory by masked individuals.”

MethodsFind in source

“Second, random assignment of 624 participants provided 88% power to demonstrate non-inferiority between treatment combinations based on a non-inferiority margin of 5%, and 99% power to demonstrate non-inferiority between treatment strategies based on a non-inferiority margin of 10%, assuming 95% SVR, a one-sided α of 0·05, and 5% loss to follow-up.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, stratification, and pre-specified analyses, though open-label and with some deviations.

Evidence

“Randomisation used a computer-generated sequential list with variably sized permuted blocks prepared by the trial statistician (LM) and incorporated securely into the online trial database.”

MethodsFind in source

Statistical analysisFind in source

Sex is reported for all participants, and age is reported as median with IQR. HCV genotype is reported in detail. Health status is described via inclusion criteria (mild-to-moderate liver fibrosis) and baseline characteristics. Demographics include age, sex, HIV status, and substance use history. Ethnicity was not collected, which is noted.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key biological variables such as sex, age, and genotype are reported, and demographics are adequately described.

Evidence

“154 (25%) patients were female”

Results ¶1Find in source

“Median age was 42 years (IQR 37–51)”

Results ¶1Find in source

“we did not collect data on ethnicity”

MethodsFind in source

PASSReviewer 2· 90% conf

Key biological variables such as sex, age, and genotype are reported, though some details like ethnicity are not collected.

Evidence

“Median age was 42 years (IQR 37–51), 154 (25%) patients were female, 84 (13%) were HIV positive (and receiving treatment, in line with the inclusion criteria), and 213 (34%) had a history of illicit substance use.”

Results ¶1Find in source

“Data on sex (male or female) were collected by self-report; we did not collect data on ethnicity.”

MethodsFind in source

The paper states ethical approval was obtained from local hospital ethics committees, the Ministry of Health, and UK institutions, with a reference number. Written informed consent was obtained from participants. Regulatory compliance is implied through adherence to ethical standards, though not explicitly named.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval from named committees and informed consent are clearly documented.

Evidence

“Ethical approval was obtained from local hospital ethics committees at the Hospital for Tropical Diseases and the National Hospital of Tropical Disease; the Ministry of Health, Viet Nam; Imperial College London, UK; and the University of Oxford, UK (ref 110-0319/35CN).”

MethodsFind in source

“Participants were recruited by the trials team from routine clinics and provided written informed consent before random assignment.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval from named committees and informed consent are documented.

Evidence

MethodsFind in source

“Participants were recruited by the trials team from routine clinics and provided written informed consent before random assignment.”

MethodsFind in source

The drugs (sofosbuvir, daclatasvir, velpatasvir, PEGylated interferon) are identified with doses and manufacturers. The viral load assays are identified with manufacturers. Statistical software (R and Stata) is named with versions. No antibodies, cell lines, or mycoplasma testing are applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products are identified with manufacturer and dose, and the statistical software is named.

Evidence

“All trial drugs were purchased at market prices through generic suppliers (direct-acting antivirals from Mylan, Mumbai, India; PEGylated interferon alfa-2a from Zuillig Pharma, Ho Chi Minh City, Viet Nam).”

MethodsFind in source

“Bayesian analyses were done with R version 4.1.3, all other analyses were done using Stata version 18.0”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Investigational products and key reagents are identified with sources, and statistical software is named.

Evidence

MethodsFind in source

“Bayesian analyses were done with R version 4.1.3, all other analyses were done using Stata version 18.0 (appendix pp 5–6).”

Statistical analysisFind in source

The primary analysis used Bayesian methods with uninformative priors, reporting risk differences and 90% CrIs. Secondary analyses used frequentist methods. Tests are named (e.g., χ², exact tests, GEE, interval regression). Assumptions are addressed through the choice of methods. Exact p-values are reported for some comparisons, but many are reported as Bayesian probabilities. Effect sizes with CIs are reported. Software is identified. Data presentation includes per-group n and percentages.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are thoroughly described, with Bayesian and frequentist approaches, and effect sizes with credible intervals are reported.

Evidence

“The proportion of participants with undetectable HCV viral load at each visit was analysed using χ 2 or exact tests and binomial generalised estimating equations with an independent correlation structure”

Statistical analysisFind in source

“SVR occurred in 294 (97%) of 302 participants in the sofosbuvir–daclatasvir group and 292 (95%) of 307 participants in the sofosbuvir–velpatasvir group (risk difference 2·2%, 90% credible interval [CrI] –0·2 to 4·8”

Results ¶3Find in source

paraphrase[Results, paragraph 3]

“P=0·069”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with Bayesian and frequentist analyses, though some p-values are reported as thresholds.

Evidence

“Primary comparisons between randomised groups were analysed using Bayesian methods with uninformative priors, calculating marginal risk differences and 90% credible intervals (CrIs) after logistic regression, reflecting the non-inferiority design, since it is implausible that giving less treatment could lead to better outcomes.”

Statistical analysisFind in source

“adverse reactions were very common in the 4-week antiviral plus interferon group compared with the other treatment strategies (risk difference vs SOC group, 66·8% [59·2 to 74·0]; p<0·0001).”

AbstractFind in source

The data sharing statement describes a controlled access approach via the OUCRU Data Access Committee, with a data access request form and agreement. This is a concrete route for accessing de-identified individual participant data. No code sharing is mentioned, but the statistical analysis is described in detail.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

A detailed data sharing statement is provided, with a controlled access mechanism and contact information.

Evidence

“All individual participant data collected during the trial, after de-identification, will therefore be available (with data dictionaries), as will the trial protocol and statistical analysis plan, from immediately following publication with no end date. Anyone wishing to access the data should contact dac@oucru.org to gain access; data requestors will need to complete a short data access request form (available from https://www.oucru.org/data-sharing-policy/ ), which will be reviewed and approved by the OUCRU Data Access Committee, and sign a data access agreement.”

Data availabilityFind in source

PASSReviewer 2· 95% conf

Data availability is clearly described with a controlled access mechanism, and the trial is registered.

Evidence

Data availabilityFind in source

The trial is registered with ISRCTN. Methods are described in detail, including procedures and statistical analysis. Limitations are explicitly discussed, including lack of masking, limited generalisability, and potential for re-infection. Conclusions are appropriately cautious, noting the need for further studies. Funding and conflicts of interest are declared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional to the evidence.

Evidence

“This trial is registered with ISRCTN, 61522291.”

MethodsFind in source

“Limitations of this study include the fact that the trial only included individuals with mild to moderate liver disease; cure rates in those with more advanced fibrosis or cirrhosis will be lower and further work is needed to establish the role of shorter-course treatment in such individuals.”

Discussion ¶7Find in source

paraphrase[Acknowledgments and Declaration of interests]

“This study was funded by the Wellcome Trust (award number 206296/Z/17/Z). ... We declare no competing interests.”

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“This trial is registered with ISRCTN, 61522291, and is completed.”

AbstractFind in source

Discussion ¶7Find in source

Registration stated in text, but no registry ID was detected. Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 23 references by DOI: 11 verified — 12 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the minor reporting gaps (threshold p-values, lack of explicit CONSORT statement, no code sharing) and the overstated cost-saving claim. No erratum is warranted for the core findings, but the authors should consider issuing a correction for the table typos and tempering the cost-saving claim.

1.
HIGHreporting
In the Discussion, temper the claim that the induction–maintenance strategy is cost-saving to reflect that it is conditional on treatment costs being proportional to the number of tablets used.
The claim audit rated this as overstated; the paper only supports a conditional statement, not a definitive cost-saving claim.
2.
HIGHstatistics
In the Abstract and Results, replace threshold p-values (e.g., p<0·0001) with exact p-values where available, or provide them in the appendix.
Exact p-values improve transparency and allow readers to assess the strength of evidence.
3.
MEDIUMreporting
In the Methods or Acknowledgments, explicitly state adherence to the CONSORT reporting guideline.
The trial is registered and includes a CONSORT diagram, but the guideline is not named, which is a minor reporting gap.
4.
MEDIUMdata code
In the Data sharing statement, add a statement about the availability of statistical analysis code, even if standard software was used.
Enhances reproducibility and aligns with best practices for data-driven research.
5.
MEDIUMstatistics
In the Statistical analysis section, clarify the handling of missing data for the primary outcome, including any imputation methods.
The modified ITT population is defined, but imputation methods are not described, which is a common reviewer request.
6.
MEDIUMreporting
In the Methods, provide more detail on randomization sequence generation and allocation concealment to fully meet CONSORT requirements.
Reviewer 2 noted this as a gap; it strengthens the transparency of the randomization process.
7.
MEDIUMcopyedit
In Table 2, fix the typo in the header: change '4-week acting plus interferon' to '4-week antiviral plus interferon'.
Corrects a clear typo that could confuse readers.
8.
MEDIUMcopyedit
In Table 2, correct the missing minus sign in the primary efficacy comparison: change '·4·5%' to '–4·5%'.
The risk difference is negative and the missing sign is a factual error.
9.
MEDIUMcopyedit
In Table 3, fix the decimal formatting inconsistencies: change '2–3%' to '2·3%' and '59–2' to '59·2'.
Ensures consistency and accuracy in reported values.
10.
MEDIUMcopyedit
In Table 2, replace the apostrophe in '100’0%' with a middle dot: '100·0%'.
Consistent decimal formatting is expected in scientific tables.
11.
LOWreporting
In the Discussion, explicitly address how the lack of blinding might have influenced the results, beyond stating it was not possible.
Reviewer 1 suggested this; it would strengthen the interpretation of the open-label design.
12.
LOWdata code
In the Data sharing statement, specify the timeframe for data availability and any conditions for access beyond the data access agreement.
Provides clarity for potential data requestors.

Full text (55,482 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.

Read full text (PMC)

DOI

10.1016/S0140-6736(25)00097-2

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/aa776395-f75d-4f00-842e-34120838daef" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/aa776395-f75d-4f00-842e-34120838daef/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 2 high issues for “Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

7ebaf3f28c067dbfa2c675713b080ec60cc62463b8d04c7bb94489f0ec2f8658

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsStatistic did not reproduce−0.5★
IntegrityIntegrity concern−0.5★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 4 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Printed percentage does not match its own count
highArithmeticrecomputedFull detail
98.7% does not match the reported count 151/152
“151/152 (98.7%)”
Find in source
02Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is sustained virological response (SVR), defined as undetectable HCV RNA 12 weeks after treatment completion. SVR is a surrogate marker for clinical outcomes such as prevention of cirrhosis, hepatocellular carcinoma, and mortality. The manuscript does not provide evidence linking SVR to these hard clinical outcomes, nor does it demonstrate target engagement at the tested dose beyond the surrogate itself. Therefore, the efficacy claim rests on a surrogate without a validated link to clinical benefit.
“The primary endpoint was SVR, defined as plasma HCV RNA less than the lower level of quantification 12 weeks after the end of treatment without previous treatment failure.”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The induction–maintenance strategy is cost-saving.
“When treatment costs are proportional to the number of tablets used, the induction and maintenance strategy would be cost saving, although this is not the primary intent of the strategy.”
Discussion ¶8Find in source

Findings by category

201ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit5 minor suggestions

Numerical inconsistencies

2 findings · worst high

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks. 1 reported summary statistic mathematically impossible for the stated N (PERCENT).

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions overstated beyond the evidenceAssessed

7 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work, identifying a gap in head-to-head comparisons, and providing a logical rationale for the study objectives.

Evidence

Introduction ¶1Find in source

Introduction ¶3Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research and identifying a gap in head-to-head comparisons of HCV treatments.

Evidence

Introduction ¶1Find in source

Introduction ¶2Find in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, stratification, and pre-specified analyses, though blinding was not possible and was appropriately justified.

Evidence

“Randomisation used a computer-generated sequential list with variably sized permuted blocks prepared by the trial statistician (LM) and incorporated securely into the online trial database.”

MethodsFind in source

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, stratification, and pre-specified analyses, though open-label and with some deviations.

Evidence

“Randomisation used a computer-generated sequential list with variably sized permuted blocks prepared by the trial statistician (LM) and incorporated securely into the online trial database.”

MethodsFind in source

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key biological variables such as sex, age, and genotype are reported, and demographics are adequately described.

Evidence

“154 (25%) patients were female”

Results ¶1Find in source

“Median age was 42 years (IQR 37–51)”

Results ¶1Find in source

“we did not collect data on ethnicity”

MethodsFind in source

PASSReviewer 2· 90% conf

Key biological variables such as sex, age, and genotype are reported, though some details like ethnicity are not collected.

Evidence

Results ¶1Find in source

“Data on sex (male or female) were collected by self-report; we did not collect data on ethnicity.”

MethodsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval from named committees and informed consent are clearly documented.

Evidence

MethodsFind in source

“Participants were recruited by the trials team from routine clinics and provided written informed consent before random assignment.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval from named committees and informed consent are documented.

Evidence

MethodsFind in source

“Participants were recruited by the trials team from routine clinics and provided written informed consent before random assignment.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products are identified with manufacturer and dose, and the statistical software is named.

Evidence

MethodsFind in source

“Bayesian analyses were done with R version 4.1.3, all other analyses were done using Stata version 18.0”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Investigational products and key reagents are identified with sources, and statistical software is named.

Evidence

MethodsFind in source

“Bayesian analyses were done with R version 4.1.3, all other analyses were done using Stata version 18.0 (appendix pp 5–6).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are thoroughly described, with Bayesian and frequentist approaches, and effect sizes with credible intervals are reported.

Evidence

Statistical analysisFind in source

Results ¶3Find in source

paraphrase[Results, paragraph 3]

“P=0·069”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with Bayesian and frequentist analyses, though some p-values are reported as thresholds.

Evidence

Statistical analysisFind in source

“adverse reactions were very common in the 4-week antiviral plus interferon group compared with the other treatment strategies (risk difference vs SOC group, 66·8% [59·2 to 74·0]; p<0·0001).”

AbstractFind in source

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

A detailed data sharing statement is provided, with a controlled access mechanism and contact information.

Evidence

Data availabilityFind in source

PASSReviewer 2· 95% conf

Data availability is clearly described with a controlled access mechanism, and the trial is registered.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional to the evidence.

Evidence

“This trial is registered with ISRCTN, 61522291.”

MethodsFind in source

Discussion ¶7Find in source

paraphrase[Acknowledgments and Declaration of interests]

“This study was funded by the Wellcome Trust (award number 206296/Z/17/Z). ... We declare no competing interests.”

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“This trial is registered with ISRCTN, 61522291, and is completed.”

AbstractFind in source

Discussion ¶7Find in source

Registration stated in text, but no registry ID was detected. Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 23 references by DOI: 11 verified — 12 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
In the Discussion, temper the claim that the induction–maintenance strategy is cost-saving to reflect that it is conditional on treatment costs being proportional to the number of tablets used.
The claim audit rated this as overstated; the paper only supports a conditional statement, not a definitive cost-saving claim.
2.
HIGHstatistics
In the Abstract and Results, replace threshold p-values (e.g., p<0·0001) with exact p-values where available, or provide them in the appendix.
Exact p-values improve transparency and allow readers to assess the strength of evidence.
3.
MEDIUMreporting
In the Methods or Acknowledgments, explicitly state adherence to the CONSORT reporting guideline.
The trial is registered and includes a CONSORT diagram, but the guideline is not named, which is a minor reporting gap.
4.
MEDIUMdata code
In the Data sharing statement, add a statement about the availability of statistical analysis code, even if standard software was used.
Enhances reproducibility and aligns with best practices for data-driven research.
5.
MEDIUMstatistics
In the Statistical analysis section, clarify the handling of missing data for the primary outcome, including any imputation methods.
The modified ITT population is defined, but imputation methods are not described, which is a common reviewer request.
6.
MEDIUMreporting
In the Methods, provide more detail on randomization sequence generation and allocation concealment to fully meet CONSORT requirements.
Reviewer 2 noted this as a gap; it strengthens the transparency of the randomization process.
7.
MEDIUMcopyedit
In Table 2, fix the typo in the header: change '4-week acting plus interferon' to '4-week antiviral plus interferon'.
Corrects a clear typo that could confuse readers.
8.
MEDIUMcopyedit
In Table 2, correct the missing minus sign in the primary efficacy comparison: change '·4·5%' to '–4·5%'.
The risk difference is negative and the missing sign is a factual error.
9.
MEDIUMcopyedit
In Table 3, fix the decimal formatting inconsistencies: change '2–3%' to '2·3%' and '59–2' to '59·2'.
Ensures consistency and accuracy in reported values.
10.
MEDIUMcopyedit
In Table 2, replace the apostrophe in '100’0%' with a middle dot: '100·0%'.
Consistent decimal formatting is expected in scientific tables.
11.
LOWreporting
In the Discussion, explicitly address how the lack of blinding might have influenced the results, beyond stating it was not possible.
Reviewer 1 suggested this; it would strengthen the interpretation of the open-label design.
12.
LOWdata code
In the Data sharing statement, specify the timeframe for data availability and any conditions for access beyond the data access agreement.
Provides clarity for potential data requestors.

Full text (55,482 chars)Analyzed: Aug 15, 2026